Segui
Timothy D. McHugh
Timothy D. McHugh
Professor of Medical Microbiology, UCL
Email verificata su ucl.ac.uk
Titolo
Citata da
Citata da
Anno
The continuing epidemic threat of novel coronaviruses to global health-the latest novel coronavirus outbreak in Wuhang, China
DS Hui, E Ei Azhar, TA Madani, F Ntoumi, RA Kock, O Dar, G Ippolito, ...
International Journal of Infectious Diseases 91, 1920
4027*1920
The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health—The latest 2019 novel coronavirus outbreak in Wuhan, China
DS Hui, EI Azhar, TA Madani, F Ntoumi, R Kock, O Dar, G Ippolito, ...
International journal of infectious diseases 91, 264-266, 2020
40252020
Global Tuberculosis Report 2020–Reflections on the Global TB burden, treatment and prevention efforts
J Chakaya, M Khan, F Ntoumi, E Aklillu, R Fatima, P Mwaba, N Kapata, ...
International Journal of Infectious Diseases, 2021
8232021
Treatment of highly drug-resistant pulmonary tuberculosis
F Conradie, AH Diacon, N Ngubane, P Howell, D Everitt, AM Crook, ...
New England Journal of Medicine 382 (10), 893-902, 2020
7142020
Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis
SH Gillespie, AM Crook, TD McHugh, CM Mendel, SK Meredith, ...
New England Journal of Medicine 371 (17), 1577-1587, 2014
6982014
Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care test
SD Lawn, P Mwaba, M Bates, A Piatek, H Alexander, BJ Marais, ...
The Lancet infectious diseases 13 (4), 349-361, 2013
6042013
High-dose rifapentine with moxifloxacin for pulmonary tuberculosis
A Jindani, TS Harrison, AJ Nunn, PPJ Phillips, GJ Churchyard, ...
N Engl J Med 371, 1599-1608, 2014
4892014
New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects
AI Zumla, SH Gillespie, M Hoelscher, PPJ Philips, ST Cole, I Abubakar, ...
The Lancet infectious diseases 14 (4), 327-340, 2014
4172014
Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies
S Tiberi, N du Plessis, G Walzl, MJ Vjecha, M Rao, F Ntoumi, S Mfinanga, ...
The Lancet Infectious Diseases 18 (7), e183-e198, 2018
3642018
Drug-resistant tuberculosis: time for visionary political leadership
I Abubakar, M Zignol, D Falzon, M Raviglione, L Ditiu, S Masham, I Adetifa, ...
The Lancet infectious diseases 13 (6), 529-539, 2013
3612013
A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis
MJ Boeree, AH Diacon, R Dawson, K Narunsky, J Du Bois, A Venter, ...
American journal of respiratory and critical care medicine 191 (9), 1058-1065, 2015
3512015
Physiological cost of rifampin resistance induced in vitro in Mycobacterium tuberculosis
OJ Billington, TD McHugh, SH Gillespie
Antimicrobial agents and chemotherapy 43 (8), 1866, 1999
3341999
Tuberculosis: advances and challenges in development of new diagnostics and biomarkers
G Walzl, R McNerney, N du Plessis, M Bates, TD McHugh, NN Chegou, ...
The Lancet Infectious Diseases 18 (7), e199-e210, 2018
3072018
Rapid whole-genome sequencing of Mycobacterium tuberculosis isolates directly from clinical samples
AC Brown, JM Bryant, K Einer-Jensen, J Holdstock, DT Houniet, ...
Journal of clinical microbiology 53 (7), 2230, 2015
3052015
Changes in prevalence and load of airway bacteria using quantitative PCR in stable and exacerbated COPD
DS Garcha, SJ Thurston, ARC Patel, AJ Mackay, JJP Goldring, ...
Thorax 67 (12), 1075-1080, 2012
2822012
Tuberculosis diagnostics and biomarkers: needs, challenges, recent advances, and opportunities
R McNerney, M Maeurer, I Abubakar, B Marais, TD Mchugh, N Ford, ...
Journal of Infectious Diseases 205 (suppl_2), S147-S158, 2012
2712012
Is Africa prepared for tackling the COVID-19 (SARS-CoV-2) epidemic. Lessons from past outbreaks, ongoing pan-African public health efforts, and implications for the future
N Kapata, C Ihekweazu, F Ntoumi, T Raji, P Chanda-Kapata, P Mwaba, ...
International Journal of Infectious Diseases 93, 233-236, 2020
2492020
Smartphone-enabled video-observed versus directly observed treatment for tuberculosis: a multicentre, analyst-blinded, randomised, controlled superiority trial
A Story, RW Aldridge, CM Smith, E Garber, J Hall, G Ferenando, L Possas, ...
The Lancet 393 (10177), 1216-1224, 2019
2272019
The transmission of Mycobacterium tuberculosis in high burden settings
TA Yates, PY Khan, GM Knight, JG Taylor, TD McHugh, M Lipman, ...
The Lancet infectious diseases 16 (2), 227-238, 2016
2262016
Whole-genome sequencing to establish relapse or re-infection with Mycobacterium tuberculosis: a retrospective observational study
JM Bryant, SR Harris, J Parkhill, R Dawson, AH Diacon, P van Helden, ...
The Lancet Respiratory Medicine 1 (10), 786-792, 2013
2242013
Il sistema al momento non può eseguire l'operazione. Riprova più tardi.
Articoli 1–20